<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023526</url>
  </required_header>
  <id_info>
    <org_study_id>CR108609</org_study_id>
    <secondary_id>2019-000473-23</secondary_id>
    <secondary_id>74494550AML2001</secondary_id>
    <nct_id>NCT04023526</nct_id>
  </id_info>
  <brief_title>A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy</brief_title>
  <acronym>CULMINATE</acronym>
  <official_title>A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of cusatuzumab in combination with&#xD;
      azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are&#xD;
      not eligible for intensive chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AML is a heterogeneous disease characterized by uncontrolled clonal expansion of&#xD;
      hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for&#xD;
      the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts&#xD;
      harvested from newly diagnosed AML participants expressed Cluster of Differentiation (CD) 70&#xD;
      on the cell surface. Cusatuzumab (JNJ-74494550) is a humanized monoclonal antibody of camelid&#xD;
      origin, binding with tight affinity to human CD70. Cusatuzumab has been modified to induce&#xD;
      enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for therapeutic use in&#xD;
      participants with cancer. Azacitidine is a pyrimidine nucleoside analogue of cytidine with&#xD;
      antineoplastic activity and is indicated for the treatment of adult participants with AML or&#xD;
      intermediate 2 and high-risk myelodysplastic syndrome (MDS) with greater than 20% marrow&#xD;
      blasts who are not eligible for hematopoietic stem cell transplantation. This study will&#xD;
      evaluate 2 doses of cusatuzumab in combination with standard dose azacitidine in participants&#xD;
      with AML who are not candidates for intensive chemotherapy (Part 1). Part 1 data will be&#xD;
      reviewed by a Data Review Committee to select a preferred dose of cusatuzumab. The study will&#xD;
      include a Screening Phase (28 days prior to randomization), a Treatment Phase, and a&#xD;
      Follow-up Phase. The study includes evaluations like vital signs, electrocardiogram,&#xD;
      spirometry test, serum chemistry and hematology tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Response (CR)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR with Partial Hematological Recovery (CRh)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR plus CRh</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR with Incomplete Recovery (CRi)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR without MRD</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level &lt;10^-3; determined by central lab).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as less than (&lt;) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level &lt;10^-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Time to response, defined as time from randomization in Part 1 to achieving the first response of CR, CRh, or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to disease relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) or Platelets Transfusion Independence</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Cusatuzumab</measure>
    <time_frame>Up to 2 years and 2 months</time_frame>
    <description>Cmin is the minimum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Cusatuzumab</measure>
    <time_frame>Up to 2 years and 2 months</time_frame>
    <description>Cmax is the maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-cusatuzumab Antibodies</measure>
    <time_frame>Up to 3 years and 5 months</time_frame>
    <description>Number of participants exhibiting anti-drug antibodies for cusatuzumab alone and in combination with azacitidine will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle.</description>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cusatuzumab</intervention_name>
    <description>Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.</description>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
    <other_name>JNJ-74494550</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia (AML) according to World Health Organisation (WHO) 2016&#xD;
             criteria and fulfilling all of the following criteria that defines those who are &quot;not&#xD;
             candidates for intensive chemotherapy&quot;:&#xD;
&#xD;
               1. greater than or equal to (&gt;=)75 years of age or&#xD;
&#xD;
               2. less than (&lt;) 75 years of age with at least one of the following comorbidities:&#xD;
                  Eastern Cooperative Oncology Group (ECOG) Performance Status of 2; Severe cardiac&#xD;
                  comorbidity defined as congestive heart failure or ejection fraction less than or&#xD;
                  equal to (&lt;=) 50 percent (%); Severe pulmonary comorbidity defined as documented&#xD;
                  pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) &lt;=65%&#xD;
                  of expected, or forced expiratory volume in 1 second (FEV1) &lt;=65% of expected or&#xD;
                  dyspnea at rest requiring oxygen; Moderate hepatic impairment defined according&#xD;
                  to NCI organ dysfunction classification criteria (total bilirubin &gt;=1.5 up to 3&#xD;
                  times upper limit of normal [ULN]); Creatinine clearance &lt;45 milliliter per&#xD;
                  minute per 1.73 meter square (mL/ min/1.73 m^2); Comorbidity that, in the&#xD;
                  Investigator's opinion, makes the participant unsuitable for intensive&#xD;
                  chemotherapy and must be documented and approved by the Sponsor before&#xD;
                  randomization&#xD;
&#xD;
          -  De novo or secondary AML&#xD;
&#xD;
          -  Previously untreated AML (except: emergency leukapheresis, hydroxyurea, and/or 1 dose&#xD;
             of cytarabine [example: 1-2 gram per meter square {g/m^2}] during the Screening Phase&#xD;
             to control hyperleukocytosis. These treatments must be discontinued &gt;=24 hours prior&#xD;
             to start of study drug). Empiric all trans retinoic acid (ATRA) treatment for presumed&#xD;
             acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA&#xD;
             must be discontinued &gt;=24 hours prior to the start of study drug&#xD;
&#xD;
          -  Not eligible for an allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  ECOG Performance Status score of 0, 1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Leukemic involvement or clinical symptoms of leukemic involvement of the central&#xD;
             nervous system&#xD;
&#xD;
          -  Use of immune suppressive agents for the past 4 weeks before the first administration&#xD;
             of cusatuzumab on Cycle 1 Day 3. For regular use of systemic corticosteroids,&#xD;
             participants may only be included if free of systemic corticosteroids for a minimum of&#xD;
             5 days before the first administration of cusatuzumab. Treatment of adrenal&#xD;
             insufficiency with physiologic replacement doses of corticosteroids are allowed&#xD;
&#xD;
          -  Prior treatment with a hypomethylating agent for treatment of AML or myelodysplastic&#xD;
             syndrome (MDS)&#xD;
&#xD;
          -  Active malignancies (that is, progressing or requiring treatment in the last 24&#xD;
             months) other than the disease being treated under the study&#xD;
&#xD;
          -  Any active systemic infection&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its&#xD;
             excipients (that is, mannitol, an excipient of azacitidine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincents Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual de Campinas - Centro de Hematologia e Hemoterapia</name>
      <address>
        <city>Campinas</city>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre - Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology, Cardarelli Hospital</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinck Regional Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ekaterinburg City Clinical Hospital # 7</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin Moscow City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 40</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod Region Clinical Hospital</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Hospital</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City clinical hospital #15</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Region Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologic Dispensary No.2</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Petersburg Clinical Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komi Republic Oncology dispensary</name>
      <address>
        <city>Syktyvkar</city>
        <zip>167904</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Cat. Doncologia-H Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Son Espases</name>
      <address>
        <city>Palma</city>
        <zip>7120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Quiron Madrid Pozuelo</name>
      <address>
        <city>Pozuelo De Alarcon, Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. I Politecni La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSELSPITAL, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulhane Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Hematology Department - Hematology</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Universitesi Tip Fakultesi</name>
      <address>
        <city>Atakum</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

